Shengshi Jinghua (Beijing) Biotechnology Co., Ltd. was founded in 2018 with a registered capital of 50 million, and entered the field of medical and health. Its purpose is to transform scientific and technological achievements, and focus on the fields of pathogen diagnosis and hypersensitivity diagnosis of infectious and infectious diseases, early diagnosis of tumor, hypersensitive diagnosis of fatty liver inflammation and tumor biotherapy.

At present, the company has scientific research cooperation with Shanghai Medical University, Institute of biophysics of Chinese Academy of Sciences, Tianjin University Research Institute, Beijing You'an Hospital, Beijing Institute of liver disease, etc. at the same time, it has deep strategic cooperation with China Resources pharmaceutical, Xinhua medical, natong technology, Lianying technology and other enterprises, and has established friendly cooperative relations with dozens of hospitals in China Diagnosis and tumor biotherapy have great advantages. The company is preparing to set up a biological laboratory in Daxing health industry base, covering an area of nearly 1000 square meters, engaged in professional research on medical diagnosis and tumor biotherapy. By taking advantage of the unique advantage of rich clinical resources in China, based on the advantageous scientific research and technology platform of Institute of Biophysics, Chinese Academy of Sciences and Beijing Institute of liver diseases, and integrating domestic and foreign research teams for collective scientific research, we can comprehensively promote the development of translational medicine research in China and realize a bright future of win-win cooperation.